Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Duchenne muscular Dystrophy
100%
Spinal muscular Atrophy
31%
Quantitative Ultrasound
21%
Gene Therapy
19%
Onasemnogene Abeparvovec
19%
Ultrasound
18%
Delandistrogene Moxeparvovec
18%
Electrical Impedance Myography
16%
Nerve
13%
Backscatter
13%
Givinostat
12%
Backscatter Analysis
11%
Dystrophin
11%
Ultrasound Examination
11%
Young children
10%
Quantitative muscle Ultrasound
10%
Disease Progression
10%
Grayscale Level
9%
Electrodiagnosis
9%
Nusinersen
9%
Infant Boys
9%
Muscular Dystrophy
9%
Corticosteroids
9%
Randomized Double-blind
9%
SMN2
9%
Viltolarsen
9%
Becker muscular Dystrophy
9%
Placebo-controlled
9%
Polyneuropathy
9%
Adverse Events
8%
Muscle Thickness
8%
United States
8%
Nerve Enlargement
8%
SMN2 Copies
7%
Spinal muscular Atrophy Type 1
7%
Safety/tolerability
7%
Clinical Trials
7%
Skeletal muscle
7%
Placebo
7%
Neuromuscular Ultrasound
7%
Non-ambulatory
6%
Nerve Ultrasound
6%
Ambulatory Patients
6%
Natural History
6%
Intraclass Correlation Coefficient
6%
Myopathy
6%
Phase II Trial
6%
Non-ambulatory Patient
6%
Intramuscular Blood Flow
6%
Phase 3 Trial
6%
Medicine and Dentistry
Duchenne Muscular Dystrophy
76%
Gene Therapy
21%
Spinal Muscular Atrophy
21%
Adverse Event
16%
Dystrophin
16%
Onasemnogene Abeparvovec
15%
Myography
13%
Corticosteroid
12%
Ultrasonography of Muscle
12%
Skeletal Muscle
12%
Upper Limb
10%
Electrodiagnosis
10%
Disease Exacerbation
9%
Placebo
9%
Myopathy
9%
Viltolarsen
9%
Neuromuscular Disease
8%
Arm
8%
Muscle Disease
8%
Exon
8%
Echography
7%
Clinical Trial
7%
Nusinersen
6%
Magnetic Resonance Imaging
6%
Pediatrics
6%
Diseases
6%
Becker Muscular Dystrophy
6%
Givinostat
6%
Neuropathy
6%
Nerve Transplantation
6%
Chronic Inflammatory Demyelinating Polyneuropathy
6%
Blood Flow
6%
Myasthenia gravis
6%
Muscular Dystrophy
5%
Limb
5%
Motor Neuron
5%
Median Nerve
5%